{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:20Z","timestamp":1790096900638,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K05278"],"award-info":[{"award-number":["JP25K05278"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104782","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:25Z","timestamp":1787181865000},"page":"104782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["China\u2019s drug discovery strategy: established targets, combination approaches, and small-molecule optimization"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-7741","authenticated-orcid":false,"given":"Ryo","family":"Okuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104782_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104576","article-title":"Shifting global drug discovery landscape and the critical role of startups in strengthening national capabilities","volume":"31","author":"Okuyama","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104782_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104588","article-title":"Geopolitical contributions to pharmaceutical innovation","volume":"31","author":"Kinch","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104782_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104672","article-title":"National differences in drug discovery and the role of startups: insights from cross-national analysis of phase III candidates","volume":"31","author":"Okuyama","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104782_b0020","unstructured":"Information Technology & Innovation Foundation. China\u2019s Biopharmaceutical Strategy: Challenge or Complement to U.S. Industry Competitiveness? Published August 12, 2019. Accessed March 20, 2026. https:\/\/itif.org\/publications\/2019\/08\/12\/chinas-biopharmaceutical-strategy-challenge-or-complement-us-industry\/."},{"key":"10.1016\/j.drudis.2026.104782_b0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103370","article-title":"Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020\u20132022","volume":"27","author":"Luo","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104782_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0040","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104782_b0045","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802611795429185","article-title":"Target validation: linking target and chemical properties to desired product profile","volume":"11","author":"Wyatt","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2026.104782_b0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","article-title":"Evolution of innovative drug R&D in China","volume":"21","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0055","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/d41573-024-00120-5","article-title":"Chinese innovative drug R&D trends in 2024","volume":"23","author":"Chen","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/d41586-026-00387-1","article-title":"China\u2019s biotech boom: why the nation must collaborate to stay ahead","volume":"650","author":"Lee","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104782_b0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41573-022-00077-3","article-title":"Trends in innovative drug development in China","volume":"21","author":"Su","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s43441-022-00472-3","article-title":"Trends and characteristics of new drug approvals in China, 2011\u20132021","volume":"57","author":"Su","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104782_b0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-025-02267-y","article-title":"Current landscape of innovative drug development and regulatory support in China","volume":"10","author":"Tan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104782_b0080","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/pharmaceutics15071794","article-title":"Chronological analysis of first-in-class drugs approved from 2011 to 2022: their technological trend and origin","volume":"15","author":"Okuyama","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104782_b0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41587-019-0316-7","article-title":"The next biotech superpower","volume":"37","author":"Editorial","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104782_b0090","unstructured":"Kuchler H, Xueqiao W. Rapid trials prompt deals rush for Chinese \u2018super me-too\u2019 drugs. Financial Times 2025; February 6. Accessed 5 May 2026."},{"key":"10.1016\/j.drudis.2026.104782_b0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/17460441.2016.1182484","article-title":"An industry perspective on drug target validation","volume":"11","author":"Jones","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104782_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105037","article-title":"The evolving landscape of antibody-based cancer therapies: from monospecific to multi-specific and beyond","volume":"217","author":"Okpasuo","year":"2026","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:15:04Z","timestamp":1790093704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462600187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S135964462600187X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104782","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"China\u2019s drug discovery strategy: established targets, combination approaches, and small-molecule optimization","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104782"}}